Premier Biomedical Recognized for Huge Growth Potential
Dec 15, 2015
OTC Disclosure & News Service
-
Premier Biomedical, Inc.(OTCQB: "BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that Seraphim Strategies, LLC has named Premier Biomedical, Inc. as one of five small cap stocks that they believed could experience huge growth potential.
The report stated, "Another small cap with big aspirations is Premier Biomedical (BIEI), Inc. (sic) The company focuses on new alternative treatments for a wide range of diseases, with a special focus on breast cancer and alternatives to chemotherapy. A scientist working closely with the company and its resources was recently invited to present findings at the San Antonio Breast Cancer symposium."
You can read the entire article here.
William A. Hartman, President and CEO of Premier, said of the article, “We are pleased that our potential is beginning to be recognized. Besides our innovative, extracorporeal (outside the body) treatment for blood borne-diseases, including breast cancer, we are working on bringing relief to those suffering from fibromyalgia and neuropathic pain with our patented drug, Feldetrex®, for which we plan on initiating regulatory testing in the near future. We are in the process of exploring joint ventures with established drug companies in other parts of the world to bring these treatments to patients as quickly as possible.” Contact William Hartman at 724-633-7033, PR@premierbiomedical.com.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via license agreements, the technology behind multiple provisional patents in the United States and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center. The company's R&D efforts are centered in El Paso, TX. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI".
For more information, please visit our website http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Dec 15, 2015
OTC Disclosure & News Service
-
Premier Biomedical, Inc.(OTCQB: "BIEI"
a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, announced today that Seraphim Strategies, LLC has named Premier Biomedical, Inc. as one of five small cap stocks that they believed could experience huge growth potential. The report stated, "Another small cap with big aspirations is Premier Biomedical (BIEI), Inc. (sic) The company focuses on new alternative treatments for a wide range of diseases, with a special focus on breast cancer and alternatives to chemotherapy. A scientist working closely with the company and its resources was recently invited to present findings at the San Antonio Breast Cancer symposium."
You can read the entire article here.
William A. Hartman, President and CEO of Premier, said of the article, “We are pleased that our potential is beginning to be recognized. Besides our innovative, extracorporeal (outside the body) treatment for blood borne-diseases, including breast cancer, we are working on bringing relief to those suffering from fibromyalgia and neuropathic pain with our patented drug, Feldetrex®, for which we plan on initiating regulatory testing in the near future. We are in the process of exploring joint ventures with established drug companies in other parts of the world to bring these treatments to patients as quickly as possible.” Contact William Hartman at 724-633-7033, PR@premierbiomedical.com.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via license agreements, the technology behind multiple provisional patents in the United States and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center. The company's R&D efforts are centered in El Paso, TX. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI".
For more information, please visit our website http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
